JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

Home・Akciju saraksts・Treace Medical Concepts Inc

Treace Medical Concepts Inc

Slēgts

1.83 1.1

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

1.77

Max

1.9300000000000002

Galvenie mērījumi
By Trading Economics
Ienākumi	6.9M -9.4M
Pārdošana	12M 63M
Peļņas marža	-15.026
Darbinieki	450
EBITDA	7M -5.2M

Rekomendācijas
By TipRanks
Rekomendācijas	Neitrāls
Prognoze 12 mēnešiem	+122.95% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 7. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-448K 128M
Iepriekšējā atvēršanas cena	0.73
Iepriekšējā slēgšanas cena	1.83

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bullish Evidence

7.16 / 7.65 Atbalsts un pretestība

Treace Medical Concepts Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 23. apr. 00:00 UTC

Galvenie ziņu notikumi

Australian Flash PMI Bounce in April Conceals Deeper Worries

2026. g. 22. apr. 23:33 UTC

Peļņas

SK Hynix Posts Record Quarterly Results Amid AI Boom

2026. g. 22. apr. 22:40 UTC

Peļņas

Correction to ServiceNow Posts 22% 1Q Revenue Growth Article

2026. g. 22. apr. 22:10 UTC

Iegādes, apvienošanās, pārņemšana

ServiceNow Says $4 Billion Term Loan Credit Deal Will Help Finance Armis Security Deal

2026. g. 22. apr. 21:11 UTC

Peļņas

ServiceNow Posts 22% 1Q Revenue Growth, But Says Armis Deal Will Weigh on Margins

2026. g. 22. apr. 21:01 UTC

Peļņas

IBM Posts Higher 1Q Sales, Buoyed by AI -- Update

2026. g. 22. apr. 23:46 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 22. apr. 23:46 UTC

Tirgus saruna

Nikkei May Remain Rangebound; Middle East Conflict in Focus -- Market Talk

2026. g. 22. apr. 23:34 UTC

Tirgus saruna

Galvenie ziņu notikumi

Gold Falls as U.S.-Iran Cease-Fire Keeps Inflation Concerns High -- Market Talk

2026. g. 22. apr. 23:16 UTC

Peļņas

SK Hynix: Quarterly Revenue, Profits at All-Time High in 1Q

2026. g. 22. apr. 23:15 UTC

Peļņas

SK Hynix: Operating Profit Margin Reached Record 72% in 1Q

2026. g. 22. apr. 22:54 UTC

Peļņas

SK Hynix 1Q Net Profit Beat FactSet-Compiled Consensus

2026. g. 22. apr. 22:54 UTC

Peļņas

SK Hynix 1Q Net KRW40.346T Vs. Net KRW8.108T >000660.SE

2026. g. 22. apr. 22:52 UTC

Peļņas

SK Hynix 1Q Oper Pft KRW37.610T Vs. Pft KRW7.441T >000660.SE

2026. g. 22. apr. 22:51 UTC

Peļņas

SK Hynix 1Q Rev KRW52.576T Vs. KRW17.639T >000660.SE

2026. g. 22. apr. 22:31 UTC

Peļņas

Sandfire CEO: Delivery Risk, Input Cost Pressure Could Rise Quickly If Situation Deteriorates

2026. g. 22. apr. 22:31 UTC

Peļņas

Sandfire CEO: First, Second Order Impacts of Middle East Conflict Remain Hard to Predict

2026. g. 22. apr. 22:30 UTC

Peļņas

Sandfire CEO: Middle East Conflict Creates Significant Risk in Global Supply Chains

2026. g. 22. apr. 22:30 UTC

Peļņas

Sandfire: FY26 Underlying Operating Unit Costs Expected to 'Materially Aligned' With Guidance

2026. g. 22. apr. 22:29 UTC

Peļņas

Sandfire Resources 3Q Unaudited Underlying Ebitda $220 Million

2026. g. 22. apr. 22:28 UTC

Peļņas

Sandfire Resources 3Q Unaudited Sales Revenue $408 Million

2026. g. 22. apr. 22:28 UTC

Peļņas

Sandfire Resources 3Q Motheo Underlying Operating Unit Cost $44/Ton Ore Processed

2026. g. 22. apr. 22:27 UTC

Peļņas

Sandfire Resources 3Q Matsa Underlying Operating Unit Cost $95/Ton Ore Processed

2026. g. 22. apr. 22:06 UTC

Tirgus saruna

Peļņas

Tesla Paid Robotaxi Miles Nearly Doubled Quarter-Over-Quarter -- Market Talk

2026. g. 22. apr. 21:55 UTC

Iegādes, apvienošanās, pārņemšana

ServiceNow Says $4B Term Loan Credit Deal Will Help Finance Armis Security Deal

2026. g. 22. apr. 21:47 UTC

Peļņas

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

2026. g. 22. apr. 21:37 UTC

Peļņas

Texas Instruments Reports Solid Earnings. The Stock Is Up. -- Barrons.com

2026. g. 22. apr. 21:34 UTC

Peļņas

Tesla Surprises Wall Street With Better Profits, $1.4 Billion in Free Cash Flow -- 3rd Update

2026. g. 22. apr. 21:29 UTC

Peļņas

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

2026. g. 22. apr. 21:20 UTC

Tirgus saruna

Peļņas

Tesla Expands Manufacturing to Chips -- Market Talk

Salīdzinājums

Cenas izmaiņa

Treace Medical Concepts Inc Prognoze

Cenas mērķis

By TipRanks

122.95% augšup

Prognoze 12 mēnešiem

Vidējais 4.08 USD 122.95%

Augstākais 7 USD

Zemākais 2.25 USD

Pamatojoties uz 4 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Treace Medical Concepts Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Neitrāls

4 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 4 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Treace Medical Concepts Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

7.16 / 7.65Atbalsts un pretestība

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

There is one bullish event.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Treace Medical Concepts Inc

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible realignment, stabilization, and fusion of the midfoot. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.